The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.

Ring Therapeutics is turning to a previously unexplored family of viruses to improve the safety and efficacy of gene therapy. The preclinical science suggests using these anelloviruses as vectors can deliver payloads precisely and without causing a significant immune response. Human trials will need to demonstrate the technology can live up to its disruptive potential.

Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.

Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.